Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Reform and the Biopharma Sector: A Complete Tactical Victory

This article was originally published in RPM Report

Executive Summary

The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?

Related Content

"Dollars for Donuts" Deal Revisited: What Pharma Got
Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
Pharma's Stake In Essential Health Benefits
Price Controls in Action: Understanding the Rise of the 340B Program
Job One for Big Pharma: Repositioning in DC Post-Health Care Reform
Health Care Reform and the Changing Dynamics Between Payers and Drug Makers
340B: A Test Market for Health Care Reform?
Opening A Door To Biosimilars In The US
Taking Lumps From Health Care Reform
Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts